• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

    7/15/24 8:19:45 AM ET
    $DKS
    $MRNA
    $REGN
    $SGH
    Other Specialty Stores
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DKS alert in real time by email

    The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.

    When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

    Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform.

    DICK’S Sporting Goods

    • The Trade: DICK’S Sporting Goods, Inc. (NYSE:DKS) Director Desiree Ralls-Morrison sold a total of 3,489 shares at an average price of $206.65. The insider received around $721,002 from selling those shares.
    • What's Happening: On May 29, Dick’s Sporting Goods reported better-than-expected first-quarter FY24 earnings and raised the outlook.
    • What DICK’S Sporting Goods Does: Dick’s Sporting Goods retails athletic apparel, footwear, and equipment for sports.

    Have a look at our premarket coverage here

    Regeneron Pharmaceuticals

    • The Trade: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP General Counsel and Secretary Joseph J Larosa sold a total of 1,866 shares at an average price of $1,088.95. The insider received around $2.03 million from selling those shares.
    • What's Happening: On July 11, Morgan Stanley analyst Matthew Harrison maintained Regeneron Pharmaceuticals with an Overweight and lowered the price target from $1,183 to $1,182.
    • What Regeneron Pharmaceuticals Does: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

    SMART Global Holdings

    • The Trade: SMART Global Holdings, Inc. (NASDAQ:SGH) President, LED Solutions Joseph Gates Clark sold a total of 5,000 shares at an average price of $29.00. The insider received around $145,006 from selling those shares.
    • What's Happening: On July 9, SMART Global reported better-than-expected third-quarter financial results.
    • What SMART Global Does: SMART Global Holdings Inc is a designer and manufacturer of electronic products focused on memory and computing technology areas.

    Moderna

    • The Trade: Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold a total of 15,000 shares at an average price of $117.08. The insider received around $1.8 million from selling those shares.
    • What's Happening: Moderna is expected to report its second quarter financial results on Thursday, Aug. 1.
    • What Moderna Does: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018.

    Check This Out:

    • How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings
    Get the next $DKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DKS
    $MRNA
    $REGN
    $SGH

    CompanyDatePrice TargetRatingAnalyst
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Regeneron Pharmaceuticals Inc.
    $REGN
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Regeneron Pharmaceuticals Inc.
    $REGN
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    Dick's Sporting Goods Inc
    $DKS
    11/26/2025$255.00 → $245.00Outperform
    Telsey Advisory Group
    Regeneron Pharmaceuticals Inc.
    $REGN
    11/24/2025$798.00Buy
    Truist
    Regeneron Pharmaceuticals Inc.
    $REGN
    11/24/2025$255.00Buy
    HSBC Securities
    More analyst ratings

    $DKS
    $MRNA
    $REGN
    $SGH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Regeneron Pharma upgraded by BofA Securities with a new price target

    BofA Securities upgraded Regeneron Pharma from Underperform to Buy and set a new price target of $860.00

    1/7/26 8:45:07 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DKS
    $MRNA
    $REGN
    $SGH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DKS
    $MRNA
    $REGN
    $SGH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Hoge Stephen exercised 160,009 shares at a strike of $19.15 and sold $7,814,840 worth of shares (160,009 units at $48.84) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    2/25/26 4:49:00 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Zoghbi Huda Y exercised 1,638 shares at a strike of $376.69 and sold $1,279,812 worth of shares (1,638 units at $781.33) (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/23/26 4:55:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mock James M covered exercise/tax liability with 1,278 shares and was granted 2,630 shares, increasing direct ownership by 3% to 45,224 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    2/13/26 4:41:15 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DKS
    $MRNA
    $REGN
    $SGH
    SEC Filings

    View All

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Moderna, Inc. (0001682852) (Filer)

    2/13/26 7:02:14 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DKS
    $MRNA
    $REGN
    $SGH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eddy Robert W. bought $501,053 worth of shares (2,637 units at $190.01), increasing direct ownership by 77% to 6,048 units (SEC Form 4)

    4 - DICK'S SPORTING GOODS, INC. (0001089063) (Issuer)

    6/27/25 5:01:01 PM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DKS
    $MRNA
    $REGN
    $SGH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

    Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarrytown, February 27, 2026. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the EU

    2/27/26 7:03:09 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

    If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent® (dupilumab) in the European Union (EU) for the treatment of chronic spontane

    2/27/26 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

    Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States' oldest and most prestigious science and mathematics competition for high school seniorsSince the start of Regeneron's sponsorship in 2017 through this year's STS, Regeneron and the Society have engaged and inspired more than 20,000 of the nation's top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizesRegeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of Society for Science and the

    2/26/26 12:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DKS
    $MRNA
    $REGN
    $SGH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dick's Sporting Goods Inc

    SC 13G/A - DICK'S SPORTING GOODS, INC. (0001089063) (Subject)

    11/14/24 12:00:15 PM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Dick's Sporting Goods Inc (Amendment)

    SC 13D/A - DICK'S SPORTING GOODS, INC. (0001089063) (Subject)

    3/19/24 4:05:51 PM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    $DKS
    $MRNA
    $REGN
    $SGH
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DICK'S Sporting Goods Names Matthew Barnes President, Foot Locker International

    PITTSBURGH, Nov. 25, 2025 /PRNewswire/ -- DICK'S Sporting Goods today announced the appointment of Matthew Barnes as President of Foot Locker International, effective December 3, 2025. Barnes will lead the Foot Locker business' international operations with a focus on driving strategic growth, accelerating business momentum and executing targeted turnaround strategies. In his position at Foot Locker, now part of DICK'S Sporting Goods following its acquisition in September 2025, Barnes will oversee the Foot Locker stores, eCommerce and digital businesses across Europe, Asia and

    11/25/25 2:00:00 AM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    DICK'S Sporting Goods Completes Acquisition of Foot Locker

    PITTSBURGH, Sept. 8, 2025 /PRNewswire/ -- DICK'S Sporting Goods, Inc. ("DICK'S" or the "Company") (NYSE:DKS), a leading U.S.-based full-line omni-channel sporting goods retailer, today announced that it has completed its acquisition of Foot Locker, Inc. ("Foot Locker"), a leading footwear and apparel retailer. DICK'S is now positioned to become a global leader in the sports retail industry at the intersection of sport and culture, serving a broader set of consumers across compelling, differentiated concepts. As a combined company, DICK'S will now operate more than 3,200 stores

    9/8/25 8:00:00 AM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    $DKS
    $MRNA
    $REGN
    $SGH
    Financials

    Live finance-specific insights

    View All

    DICK'S Sporting Goods, Inc. Fourth Quarter Results Call Scheduled for March 12th

    PITTSBURGH, Feb. 6, 2026 /PRNewswire/ -- DICK'S Sporting Goods, Inc. (NYSE:DKS) will announce results for the fourth quarter and full year 2025 before the market opens on Thursday, March 12th.      A conference call to discuss the results will be held that day at 10:00 a.m. Eastern Time. The call is being webcast and can be accessed at DICK'S Sporting Goods' Investor Relations website at investors.dicks.com. To listen to the live call, please go to the website at least fifteen minutes early to register and download and install any necessary audio software. A playback of the ca

    2/6/26 8:00:00 AM ET
    $DKS
    Other Specialty Stores
    Consumer Discretionary

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care